RAPP vs DBVT vs IMVT vs ABBV

AbbVie Inc.

(ABBV) offers the better valuation at 85. 5x trailing P/E (14. 3x forward), making it the more compelling value choice. Analysts rate Rapport Therapeutics, Inc. Common Stock (RAPP) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +101. 3%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: ABBV returned +295. 5% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 34β versus Rapport Therapeutics, Inc. Common Stock's 1. 55β — meaning RAPP is approximately 357% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Rapport Therapeutics, Inc.

Common Stock grew EPS 24. 3% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AbbVie Inc.

(ABBV) is the more profitable company, earning 6. 9% net margin versus -536. 4% for Rapport Therapeutics, Inc. Common Stock — meaning it keeps 6. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus -611. 0% for RAPP. At the gross margin level — before operating expenses — ABBV leads at 70. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DBVT: 131.

8% to $46. 33.

In this comparison, ABBV (3.

2% yield) pays a dividend. RAPP, DBVT, IMVT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 34), 3. 2% yield, +295. 5% 10Y return). Rapport Therapeutics, Inc. Common Stock (RAPP) carries a higher beta of 1. 55 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABBV: +295. 5%, RAPP: +92. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: RAPP is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; IMVT is a small-cap quality compounder stock; ABBV is a large-cap income-oriented stock. ABBV pays a dividend while RAPP, DBVT, IMVT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.